Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2021 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
CGEM on Nasdaq
Shares outstanding
58,837,653
Price per share
$10.35
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
61,075,479
Total reported value
$362,176,402
% of total 13F portfolios
0%
Share change
-1,415,971
Value change
-$12,503,421
Number of holders
142
Price from insider filings
$10.35
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Lynx1 Capital Management LP 14% +100% $50,697,778 +$24,599,905 8,549,084 +94% Lynx1 Capital Management LP 08 Oct 2025
VANGUARD GROUP INC 5% $17,453,917 2,943,325 The Vanguard Group 30 Sep 2025
Flynn James E 5% $17,357,187 2,927,013 Deerfield Mgmt, L.P. 30 Sep 2025
FRANKLIN RESOURCES INC 3.8% $17,836,873 2,191,262 Franklin Resources, Inc. 30 Sep 2024
CITADEL ADVISORS LLC 3.4% -34% $11,794,219 -$6,049,899 1,988,907 -34% Kenneth Griffin 30 Sep 2025

As of 30 Sep 2025, 142 institutional investors reported holding 61,075,479 shares of Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM). This represents 104% of the company’s total 58,837,653 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM) together control 91% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
MPM BIOIMPACT LLC 13% 7,648,268 0% 7.4% $45,354,229
Lynx1 Capital Management LP 9.8% 5,766,090 +31% 7% $34,192,914
BVF INC/IL 9.8% 5,750,683 0% 1.4% $34,101,550
BlackRock, Inc. 7.1% 4,169,962 -1.1% 0% $24,727,874
VANGUARD GROUP INC 5% 2,943,325 -2.5% 0% $17,453,917
DEERFIELD MANAGEMENT COMPANY, L.P. 5% 2,927,013 -24% 0.27% $17,357,187
Blue Owl Capital Holdings LP 4.3% 2,510,972 +5.2% 4.6% $14,890,064
Kynam Capital Management, LP 3.9% 2,302,172 +9.8% 1% $13,651,880
CITADEL ADVISORS LLC 3.4% 1,984,407 -24% 0.01% $11,767,533
ORBIMED ADVISORS LLC 3.3% 1,923,855 0% 0.27% $11,408,460
RTW INVESTMENTS, LP 2.9% 1,705,960 0% 0.12% $10,116,343
STATE STREET CORP 2.9% 1,677,314 +4.3% 0% $9,946,472
FRANKLIN RESOURCES INC 2.4% 1,416,036 -36% 0% $8,397,094
VR ADVISER, LLC 2.3% 1,379,965 0% 0.46% $8,183,192
GEODE CAPITAL MANAGEMENT, LLC 2.2% 1,295,320 +1.2% 0% $7,682,565
Siren, L.L.C. 2% 1,193,410 0% 0.28% $7,076,921
DIMENSIONAL FUND ADVISORS LP 2% 1,183,821 -7.3% 0% $7,020,205
Nextech Invest, Ltd. 1.9% 1,141,145 0% 1% $6,766,990
TANG CAPITAL MANAGEMENT LLC 1.9% 1,121,138 0% 0.26% $6,648,348
GOLDMAN SACHS GROUP INC 1.7% 983,960 +40% 0% $5,834,883
TWIN FOCUS CAPITAL PARTNERS, LLC 1% 595,489 0% 0.45% $3,531,250
DEUTSCHE BANK AG\ 0.97% 571,738 +0.87% 0% $3,390,406
BANK OF AMERICA CORP /DE/ 0.95% 557,189 -16% 0% $3,304,131
MILLENNIUM MANAGEMENT LLC 0.94% 550,471 +7.8% 0% $3,264,293
RENAISSANCE TECHNOLOGIES LLC 0.9% 529,408 +58% 0% $3,139,389

Institutional Holders of Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 175,391 $1,815,516 -$140,229 $10.35 4
2025 Q3 61,075,479 $362,176,402 -$12,503,421 $5.93 142
2025 Q2 62,610,123 $471,432,056 -$15,598,491 $7.53 141
2025 Q1 64,669,430 $489,559,204 -$25,799,469 $7.57 145
2024 Q4 65,580,571 $798,774,691 -$43,310,126 $12.18 144
2024 Q3 65,000,732 $1,087,002,831 -$1,185,148 $16.74 136
2024 Q2 62,920,773 $1,097,340,923 +$411,767,308 $17.44 134
2024 Q1 39,359,979 $670,698,022 +$49,224,262 $17.04 113
2023 Q4 36,858,851 $375,589,972 +$26,958,804 $10.19 110
2023 Q3 38,010,712 $344,003,620 +$11,040,871 $9.05 104
2023 Q2 36,693,312 $394,818,289 +$48,696,476 $10.76 102
2023 Q1 32,209,329 $329,495,842 -$56,320,751 $10.23 97
2022 Q4 37,711,425 $397,852,399 +$5,318,094 $10.55 94
2022 Q3 37,032,227 $474,756,845 -$7,043,826 $12.82 94
2022 Q2 37,570,810 $481,656,895 +$20,400,666 $12.82 81
2022 Q1 36,763,865 $384,914,646 +$4,824,538 $10.47 77
2021 Q4 36,386,962 $559,714,828 +$6,266,769 $15.43 74
2021 Q3 33,862,280 $762,265,836 +$33,803,888 $22.57 63
2021 Q2 32,250,659 $828,539,736 -$17,650,444 $25.75 70
2021 Q1 31,323,171 $1,298,948,827 +$1,298,948,827 $41.67 70